The global industry for tardive dyskinesia treatment is experiencing significant development. This phenomenon is fueled by a increasing prevalence of tardive dyskinesia, coupled with developments in treatment therapies. The market is defined by various variables, including drug types, distribution channels, and territories. Key stakeholders in the